{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "ORPHAN DRUG" in comments (approximate match)
Status:
Investigational
Source:
NCT03061812: Phase 3 Interventional Completed Small Cell Lung Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02449239: Phase 3 Interventional Completed Bladder Cancer
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:libivirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01963598: Phase 2 Interventional Completed Sarcopenia
(2013)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00041652: Phase 1/Phase 2 Interventional Completed Colorectal Cancer
(2000)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04666649: Phase 1 Interventional Active, not recruiting Relapsed or Refractory Acute Myeloid Leukemia
(2021)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04050462: Phase 2 Interventional Active, not recruiting Hepatocellular Carcinoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03905512: Phase 2 Interventional Completed Chronic Gout
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01574716: Phase 2 Interventional Completed Metastatic Soft Tissue Sarcoma
(2012)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02841267: Phase 1/Phase 2 Interventional Completed LGMD2I
(2016)
Source URL:
Class:
PROTEIN
